These data are in accordance with our findings that heterozygote rs35264875 is associated with an increased risk of cancer and a decreased risk of cancer metastasis indicating that TPCN2 overexpression acts as a driver of tumorigenesis and TPCN2 reduced expression acts as an enhancer of metastatic phenotypes. The gene discussed is TPCN2; the disease is cancer.